Yamane T, Nakatani H, Matsumoto H, Iwata Y, Kikuoka N, Takahashi T
First Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
Dig Dis Sci. 1998 Sep;43(9 Suppl):207S-211S.
Rebamipide is a potent antioxidative agent; it increases gastric mucosal PGE2 production and thus protects the gastric mucosa. We hypothesized that the mechanisms of ulcer formation could be extended to carcinogenesis and that an increase in gastric mucosal protection may result in a decrease in gastric carcinogenesis. Therefore, we assessed the inhibitory effects of rebamipide on N-ethyl-N'-nitro-N-nitrosoguanidine (ENNG) -induced carcinogenesis in mice. The percentage of tumor-bearing mice in three treatment groups--ENNG + rebamipide 20 mg, ENNG + rebamipide 50 mg, and ENNG alone--was 55%, 42%, and 67%, respectively. The incidence of tumorigenesis tended to decrease with increasing doses of rebamipide. The difference between ENNG + rebamipide 50 mg and ENNG alone was statistically significant (P < 0.05). These results suggest that rebamipide may strengthen the host defense mechanisms related to carcinogenesis in the digestive tract.
瑞巴派特是一种强效抗氧化剂；它可增加胃黏膜前列腺素E2的生成，从而保护胃黏膜。我们推测溃疡形成机制可能与致癌作用相关，且胃黏膜保护作用增强可能会导致胃癌发生减少。因此，我们评估了瑞巴派特对N-乙基-N'-硝基-N-亚硝基胍（ENNG）诱导的小鼠致癌作用的抑制效果。三个治疗组（ENNG + 20 mg瑞巴派特、ENNG + 50 mg瑞巴派特和单独使用ENNG）中荷瘤小鼠的百分比分别为55%、42%和67%。随着瑞巴派特剂量增加，肿瘤发生的发生率有降低趋势。ENNG + 50 mg瑞巴派特组与单独使用ENNG组之间的差异具有统计学意义（P < 0.05）。这些结果表明，瑞巴派特可能会增强与消化道致癌作用相关的宿主防御机制。
